Elucidating the neural mechanisms governing changes in individual animal behavior is a key goal in neuroscience. Such research has important implications for behavioral pharmacology and could lead to the development of treatments for psychiatric and neurological disorders. Given that the brain likely represents vast amounts of information through the combined activity of multiple neurons, studying these mechanisms requires the simultaneous recording of many neurons. Recent years have seen significant advancements in techniques for multi-cellular activity recording. Calcium imaging utilizing fluorescent sensors has emerged as a powerful method, enabling the concurrent acquisition of spatial arrangements and temporal activity changes in neuronal populations. This article focuses on deep brain imaging using GRIN lenses, particularly deep brain calcium imaging in freely behaving animals with miniaturized head-mounted microscopes. We compare the strengths and limitations of this approach to other calcium imaging methods, electrophysiological techniques, and fiber photometry. Finally, we discuss future developments in this field, including two-photon microscopy for imaging beyond cell bodies, membrane potential imaging using voltage sensors, and single-cell resolution manipulation of neural activity by integrating spatial light modulators and electrically tunable lenses.

The prevalence of allergic rhinitis (AR) reached 49.2% in 2019. In particular, the prevalence of Japanese cedar (JC) pollinosis is 38.8%, and the onset age of pollinosis is becoming younger. AR is known to be a risk factor for the development of allergic asthma, a potentially life-threatening condition. Allergen immunotherapy (AIT) is a well-documented, safe, effective treatment option for respiratory allergic disease. It has been demonstrated that AIT can provide relief from clinical symptoms and that AIT has the potential to provide long-term post-treatment effect. Unlike pharmacotherapy, AIT addresses the basic immunological mechanisms that are responsible for the development and persistence of allergic conditions. Currently, two main routes of AIT administration, subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), are commonly available. In Japan, house dust mite (HDM) SLIT tablets have been available since 2015, and JC SLIT tablet had been approved by 2018 without any age limitation. The randomized double-blind, placebo-controlled trials that included pediatric patients have been conducted in Japan. In phase II/III trail with JC SLIT tablets, treatment effect-size (improvement of clinical symptoms compared to placebo) was 46.3% after three years treatment. In addition, AR was improved in 40% (1 year) and 30% (2 years) after discontinuation of SLIT. Several future initiatives including the AIT against cedar pollen allergies were announced by Japanese government. This review covered the findings to date, including immunotherapy not only for JC pollinosis- but also for HDM-induced perennial AR.